Please login to the form below

Not currently logged in
Email:
Password:

Nycomed reports increased Q1 earnings

Nycomed has posted a 38 per cent increase in pre-tax earnings to €294.4m in the first quarter of 2011, boosted by a one off-payment of €131.1m from its marketing partner Forest Laboratories following the US approval of Daliresp

Nycomed has posted a 38 per cent increase in pre-tax earnings to €294.4m in the first quarter of 2011. This figure was boosted by a one off-payment of €131.1m from its marketing partner Forest Laboratories following the US approval of COPD drug Daliresp (roflumilast).

Its revenues increased by 15 per cent in local currencies, it said, but did not reveal the amount.

The company emphasised progress in the three leading emerging regions, with Russia/CIS registering growth of 34.9 per cent to €139.5m; Latin America growing by almost 25 per cent to €106m; Asia Pacific/Middle East and Africa up by 72 per cent to €91.8m.

Nycomed chief executive Håkan Björklund said: "Continued strong expansion in these younger markets, which we believe will be an engine for growth in our industry, helped to offset declines in Western Europe and the US, with Russia/CIS now our second-largest region after Europe, and Asia Pacific, Middle East overtaking North America in overall sales."

He added: "We believe the anticipated acquisition of Nycomed by Takeda Pharmaceutical Company Limited, announced last week, will bring together Takeda's track record of innovation and Nycomed's efficient commercialisation and manufacturing infrastructure to create a global player able to meet the needs of patients and healthcare providers around the world."

26th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics